Xin Lang Cai Jing·2026-02-15 11:49Core Viewpoint - The news highlights ongoing legal actions regarding investor claims against Yingfeituo and Ningke Biological, with recent court rulings favoring investors in both cases, indicating potential for further claims and compensation opportunities for affected shareholders [1][2][4]. Group 1: Yingfeituo (002528) - The Shenzhen Intermediate People's Court has accepted a case for investor claims against Yingfeituo, with previous rulings resulting in a win for investors [1][4]. - Investors who purchased Yingfeituo shares between April 30, 2020, and April 30, 2024, and sold or held shares after April 30, 2024, are eligible to initiate claims [2][5]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on January 24, 2025, regarding an investigation into information disclosure violations [4]. Group 2: Ningke Biological (600165) - Ningke Biological has faced legal actions due to false reporting in its 2022 annual report, which overstated revenue by 76.59 million and profit by 77.22 million, representing 11.25% and 46.59% of total revenue and profit, respectively [2][5]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and a halt in key subsidiary operations [5][6]. - Investors who bought Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3][6].